Attendee search 

Magnasense Technologies Oy

Superior immunoassay performance utilising paramagnetic labels - MagneticImmunoAssay (MIA).

Magnasense has developed a sensitive, simple and elegant system for performing lateral flow immunoassays utilising paramagnetic particles as labels.

Biological materials contain no background magnetism, enabling great sensitivity, while the elimination of chemical, enzymatic and fluorescent reagents simplifies the assay procedure.

The magnetic label interacts directly with the reader’s electronics eliminating the need for light sources and optics.

The above factors provide a uniquely sensitive, robust and inexpensive system.

The system is widely applicable. Quantitative, Near Patient / Point of Care (POC) assays and tests can be rapidly developed with high sensitivity and dynamic ranges of over four decades.
Healthcare applications include cardiac monitoring, e.g. hsCRP and infectious diseases, e.g. viruses.

Outside healthcare, assays can be developed for other applications where rapid results are required, such as veterinary testing, and food and environmental contamination

Applications:
Near Patient Testing, Point of Care Testing, Veterinary Testing, Mould / Mycotoxin testing, Food adulteration, Environmental testing

Optomeditech Oy develops patent pending breakthrough technology in the field of Intravascular Catheters. The technology uses laser light to aid in placement of the IV catheters, making the process easier, faster, safer and more reliable.

The global IV catheter market is roughly a $2B a year market that is growing 10% a year. Over 30% of first attempts to place IV catheters fail today causing significant costs and discomfort for the patients and caretakers alike. The poor placement of IV catheters is the most common cause of complaints in the hospitals. Optomeditech's product OptiVein has the technology to capture a significant portion of the IV catheter market quickly with the advantages it brings.

Optomeditech Oy has confirmed its regulatory pathway for both its CE mark and 510(k) clearance through presubmission consultation with BSI and FDA respectively and is looking to achieve CE mark by the end of Q1 2014 and 510(k) in the summer of 2014. The company is planning on entering the US market during 2015.

The company is currently conducting a clinical trial at the Helsinki University Hospital in Finland and the results have been very good to date. The clinical trial is scheduled to close at the end of August 2013.

Oppifi Oy was founded in 2007. The business idea of Oppifi is to develop, promote and sell services for storing and sharing memories the life stories.

The main product of Oppifi is a “recollection and life story” service Epooq. The service assists users to recall and tell stories with the help of digital storytelling; video, voice, photo and text. Stories can be shared to the relevant social networks – communities – by your own choise.

The chain that connects generations is built from different life stories. These stories include a wealth of personal experience, insight and learning about life and living. Life experience creates the meaning for human life.

Epooq is targeted especially for the grandparent generation, which has a lot of life experience and the need to store and share that. It was chosen a winner in the 2011 World Summit Award competition.

Epooq is sold as a service for
• Nursing homes guided groups
• Individual use active living at home

Contact Information
Oppifi Oy
Ilkka Tiainen
ilkka.tiainen@oppi.fi
www.oppi.fi

FinnMedi Oy is a service provider for technology transfer, growth company business development, regulatory issues and clinical trials. We work closely with Life Science companies assisting them to search for new markets, private and public funding and collaboration partners for R&D and to set up clinical trials. For universities we provide technology transfer services.